PharmAla Biotech Holdings, Inc. (TSE:MDMA) has released an update.
PharmAla Biotech Holdings Inc. reports a tenfold revenue increase in Q3 and solidifies its market presence by securing new opportunities in international markets. The biotech firm has strengthened its position through a permanent joint venture with Cortexa and the issuance of a US patent for its novel molecule, APA-01, which shows promise for treating a range of indications. Additionally, PharmAla acknowledges the support from IPON in securing global patents and announces a new contract and share grant for its CEO.
For further insights into TSE:MDMA stock, check out TipRanks’ Stock Analysis page.
